IP Library Granted Patent US 12,359,244
Granted Patent B2
US 12,359,244 · App. 17/374,255 · Granted Jul 15, 2025

Rapid extraction of nucleic acids from clinical samples for downstream applications

Inventors: Deborah Anne Dean (San Anselmo, CA); Noor Alnabelseya (Oakland, CA)
Assignee: The Regents of the University of California
C12Q1/6806C07H1/06C07H21/00C12Q1/689
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,359,244
App. No.
17/374,255
Granted
Jul 15, 2025
Kind
B2
Abstract

Disclosed herein are novel methods and compositions for rapidly extracting and amplifying nucleic acids from a sample where the sample is combined with an extraction reagent comprising a reducing agent to form a mixture and incubating said mixture at ambient temperature for a period of time not exceeding 30 minutes to generate a nucleic acid extract. In certain embodiments of the method, the nucleic acid extract is subjected to a nucleic acid amplification reaction. In certain aspects, oligonucleotide primers specific for nucleic acids of Chlamydia species and/or Neisseria species are added prior to initiating the amplification reaction.

Claims (22)

1. A method comprising:

incubating a mixture comprising (i) a sample suspected of comprising bacteria and (ii) an extraction reagent at ambient temperature for a period of time not exceeding 30 minutes to generate a nucleic acid extract,

wherein the reagent comprises a reducing agent, and optionally a buffer; and

combining the mixture comprising the nucleic acid extract with a nucleic acid amplification reagent under conditions that promote nucleic acid amplification of the nucleic acid extract.

2. The method of claim 1 , wherein the reducing agent is dithiothreitol (DTT).

3. The method of claim 2 , wherein the DTT is present at a concentration of 1 mM to 40 mM.

4. The method of claim 1 , wherein the reducing agent is beta mercapto-ethanol (β-ME).

5. The method of claim 4 , wherein the β-ME is present at a concentration less than or equal to 40 mM.

6. The method of claim 1 , wherein the extraction reagent comprises a buffer, and wherein the buffer provides a buffering capacity within the mixture that is less than a buffering capacity of 50 mM Tris at pH8.5.

7. The method of claim 1 , wherein the extraction reagent comprises a buffer comprising Tris at a concentration of 1.6 mM.

8. The method of claim 1 , wherein the ambient temperature ranges from 15° C. to 32° C. and the period of time does not exceed 20 minutes or 10 minutes.

9. The method of claim 1 , wherein the ambient temperature ranges from 15° C. to 32° C. and the period of time does not exceed 2 minutes or 5 minutes.

10. The method of claim 1 , wherein the bacteria comprise cysteine-rich cell walls.

11. The method of claim 1 , wherein the bacteria are selected from the group consisting of all Chlamydia species and strains and all Neisseria species and strains.

12. The method of claim 1 , wherein the nucleic acid amplification is initiated not later than 10 minutes following the conclusion of the incubation step.

13. The method of claim 1 , wherein the nucleic acid amplification is initiated not later than 5 minutes or no later than 2 minutes following the conclusion of the incubation step.

14. The method of claim 1 , wherein the nucleic acid amplification occurs via a reaction selected from the group consisting of a polymerase chain reaction (PCR), a loop-mediated isothermal amplification (LAMP), a strand displacement amplification, a multiple displacement amplification, a recombinase polymerase amplification, a helicase dependent amplification and a rolling circle amplification.

15. The method of claim 1 , wherein the nucleic acid amplification occurs via an isothermal reaction.

16. The method of claim 1 , wherein the extraction reagent comprises a detergent.

17. The method of claim 1 , wherein the extraction reagent comprises a PCR enhancer, wherein the PCR enhancer is betaine or trimethylglycine.

18. The method of claim 1 , wherein the extraction reagent comprises a magnesium salt.

19. The method of claim 1 , wherein the sample is selected from the group consisting of an endocervical swab, vaginal swab, urethral swab, pharyngeal swab, conjunctival swab and rectal swab or from remnant transport media from any of these types of swab samples.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2025
From: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 070295/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2021
From: DEAN, DEBORAH ANNE; ALNABELSEYA, NOOR
To: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
Reel/Frame 057536/0437 →
Continuity (4)
Continuation 16098736
Provisional Application 62470152 · Mar 10, 2017
Provisional Application 62331881 · May 4, 2016
Related Publication 20220017945A1 · Jan 20, 2022
References Cited (38)
US 4755356A · Robbin et al. · 1988 [cited by applicant]
US 6180778B1 · Bastian et al. · 2001 [cited by applicant]
US 7264941B1 · Birkelund et al. · 2007 [cited by applicant]
US 8691969B2 · Deggerdal et al. · 2014 [cited by applicant]
US 9206469B2 · Forman et al. · 2015 [cited by applicant]
US 11091792B2 · Dean · 2021 [cited by examiner]
US 20050112631A1 · Piepenburg et al. · 2005 [cited by applicant]
US 20050214926A1 · Zielenski et al. · 2005 [cited by applicant]
US 20110015379A1 · Mori et al. · 2011 [cited by applicant]
US 20110091883A1 · Ozsolak et al. · 2011 [cited by applicant]
US 20110236891A1 · Li et al. · 2011 [cited by applicant]
US 20110250648A1 · Manalili Wheeler et al. · 2011 [cited by applicant]
US 20110251382A1 · Deggerdal · 2011 [cited by examiner]
US 20120064511A1 · Leying Hermann et al. · 2012 [cited by applicant]
US 20120115148A1 · Kawa et al. · 2012 [cited by applicant]
US 20130017539A1 · Singhal et al. · 2013 [cited by applicant]
US 20130022963A1 · Exner et al. · 2013 [cited by applicant]
US 20140073988A1 · McSherry · 2014 [cited by applicant]
US 20140199689A1 · Voss · 2014 [cited by applicant]
US 20140212868A1 · Wilmes et al. · 2014 [cited by applicant]
US 20140256929A1 · Loes et al. · 2014 [cited by applicant]
US 20150086987A1 · Wolff et al. · 2015 [cited by applicant]
US 20150337362A1 · Tarendeau · 2015 [cited by examiner]
US 20150354005A1 · Mas Herrero et al. · 2015 [cited by applicant]
US 20150368725A1 · Ho et al. · 2015 [cited by applicant]
US 20160348189A1 · Schoenfeld · 2016 [cited by applicant]
US 20160362729A1 · Regan · 2016 [cited by examiner]
EP 0981372 · 2000 [cited by applicant]
Ahern, (1995) “Biochemical, Reagents Kits Offer Scientists Good Return on Investment”, The Scientist, vol. 9, No. 15, p. 2 (7 pages). [cited by applicant]
Amer et al., (2013) “A new approach for diagnosis of bovine coronavirus using a reverse transcription recombinase polymerase amplification assay”, Journal of Virological Methods, vol. 193, pp. 337-340. [cited by applicant]
Boyle et al., (2013) “Rapid Detection of HIV-1 Proviral DNA for Early Infant Diagnosis Using Recombinase Polymerase Amplification”, vol. 4, No. 2, e00135-13, 8 pages. [cited by applicant]
Cetus, (1988) “GeneAmp DNA amplification Reagent Kit”, 2 pages. [cited by applicant]
DTT (Dithiothreitol), Cell Signaling Technology dated Feb. 17, 2016, 1 page. [cited by applicant]
Farrell, (1999) “Evaluation of AMPLICOR Neisseria gonorrhoeae PCR Using cppB Nested PCR and 16S rRNA PCR”, Journal of Clinical Microbiology, vol. 37, No. 2, pp. 386-390. [cited by applicant]
Hackstadt et al., (1985) “Disulfide-Mediated Interactions of the Chlamydial Major Outer Membrane Protein: Role in the Differentiation of Chlamydiae?”, Journal of Bacteriology, vol. 161, No. 1, pp. 25-31. [cited by applicant]
Madico et al., (2000) “Touchdown Enzyme Time Release-PCR for Detection and Identification of Chlamydia trachomatis, C. pneumoniae, and C. psittaci Using the 16S and 16S-23S Spacer rRNA Genes”, Journal of Clinical Microb… [cited by applicant]
PCT International Preliminary Report & Written Opinion for International Application No. PCT/US2017/031138, Jul. 26, 2017, 14 pages. [cited by applicant]
PCT International Preliminary Report on Patentability, PCT Application No. PCT/US2017/031138, Nov. 15, 2018, 7 pages. [cited by applicant]